Please login to the form below

Not currently logged in
Email:
Password:

Takeda regains Prostap from Wyeth

Takeda has signed an agreement with Wyeth to regain the product licence to market Prostap in the UK and Republic of Ireland

Takeda has signed an agreement with Wyeth to regain the product licence to market Prostap in the UK and Republic of Ireland.

Under the agreement, marketing authorisation for Prostap, a prostate cancer therapy, would return to the drug's developer, Takeda. The Japanese-owned company signed over the marketing authorisation for the product in the UK and Republic of Ireland to Wyeth in 1990.

Marketing for the entire Prostap product range in the UK and Republic of Ireland will revert to Takeda from July 1, 2009.

"The addition of Prostap will enrich our product portfolio, which currently consists of Amias, Actos and Competact, and is a logical development of our plan to develop a substantial franchise in the oncology market", commented Trevor Smith, Takeda UK's managing director.

Prostap is used for the treatment of prostate cancer, endometrisis and uterine fibroids. It is marketed in around 80 countries and is considered a gold standard therapy for prostate cancer.

26th March 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Grace Communications

Grace Communications is an award winning, independent, full service, creative communications agency specialising in solving problems for healthcare brands....

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics